Cress A E, Dalton W S
Department of Radiation Oncology, Arizona Cancer Center, University of Arizona, Tucson 85724, USA.
Cancer Metastasis Rev. 1996 Dec;15(4):499-506. doi: 10.1007/BF00054015.
One major obstacle to the successful treatment of epithelial derived tumors, such as breast and prostate carcinoma, is the presence of a multiple drug resistance phenotype. The drug resistance which is observed in growing epithelial derived cancer cells could either be an intrinsic, selected and/or an acquired characteristic. A survey of the survival data from several laboratories suggests that epithelial derived tumor cells, which have never been challenged with damaging agents, are in some cases 10 to 2,000 times more resistant to various chemotherapeutic agents as compared to hematopoietic cell lines. An intrinsic characteristic of epithelial cells is their resistance to the lethal effects of multiple types of damaging agents. A major feature of epithelial derived tumors is the expression of the intermediate filament type proteins known as cytokeratin. The simplest cytokeratin combination, cytokeratin 8 and 18, is a major cytoplasmic element within the cells of epithelial derived tumors. Earlier work showed that cytokeratin could be modified by mitoxantrone, a chemotherapeutic agent used in the treatment of breast cancer. Increasing data indicates that the intrinsic drug resistance phenotype is due in part to the presence of continued expression of the cytokeratin 8 and 18. The cytokeratin dependent drug resistance (C-MDR) has been observed in two different cell types that were engineered to contain cytokeratin 8 and 18 expression. The cytokeratin monomers are known to self assemble into intermediate filament networks as shown by numerous basic studies. Experiments using transfected cell lines which are unable to assemble networks indicated that C-MDR does not depend upon the formation of an intermediate filament network. Selection of cytokeratin network defective tumor cells did not increase their sensitivity to chemotherapeutic agents. These data are interesting since it suggests that the C-MDR phenotype is not dependent upon the structural nature (i.e. network forming ability) of the cytokeratin. Our current working hypothesis is that the interaction of the damaging agent with cytokeratin may initiate signaling response(s) for cell survival.
上皮来源肿瘤(如乳腺癌和前列腺癌)成功治疗的一个主要障碍是存在多药耐药表型。在生长的上皮来源癌细胞中观察到的耐药性可能是一种内在的、选择的和/或获得性特征。对多个实验室生存数据的调查表明,从未受到损伤剂挑战的上皮来源肿瘤细胞,在某些情况下,与造血细胞系相比,对各种化疗药物的耐药性要高10到2000倍。上皮细胞的一个内在特征是它们对多种损伤剂的致死作用具有抗性。上皮来源肿瘤的一个主要特征是中间丝类型蛋白(称为细胞角蛋白)的表达。最简单的细胞角蛋白组合,细胞角蛋白8和18,是上皮来源肿瘤细胞内的主要细胞质成分。早期研究表明,细胞角蛋白可被米托蒽醌修饰,米托蒽醌是一种用于治疗乳腺癌的化疗药物。越来越多的数据表明,内在耐药表型部分归因于细胞角蛋白8和18的持续表达。在两种经过基因工程改造以含有细胞角蛋白8和18表达的不同细胞类型中观察到了细胞角蛋白依赖性耐药(C-MDR)。如众多基础研究所表明的,已知细胞角蛋白单体可自组装成中间丝网络。使用无法组装网络的转染细胞系进行的实验表明,C-MDR并不依赖于中间丝网络的形成。选择细胞角蛋白网络缺陷的肿瘤细胞并没有增加它们对化疗药物的敏感性。这些数据很有趣,因为这表明C-MDR表型不依赖于细胞角蛋白的结构性质(即网络形成能力)。我们目前的工作假设是,损伤剂与细胞角蛋白的相互作用可能引发细胞存活的信号反应。